 {"id":12418,"date":"2024-03-25T09:21:43","date_gmt":"2024-03-25T09:21:43","guid":{"rendered":"https:\/\/www.colorectalcancercanada.com\/non-classifiee\/fruquintinib-in-refractory-metastatic-colorectal-cancer\/"},"modified":"2024-03-26T13:20:10","modified_gmt":"2024-03-26T13:20:10","slug":"le-fruquintinib-dans-le-traitement-du-cancer-colorectal-metastatique-refractaire","status":"publish","type":"post","link":"https:\/\/www.colorectalcancercanada.com\/fr\/blogue\/le-fruquintinib-dans-le-traitement-du-cancer-colorectal-metastatique-refractaire\/","title":{"rendered":"Le fruquintinib dans le traitement du cancer colorectal m\u00e9tastatique r\u00e9fractaire"},"content":{"rendered":"<p>Avril 2024<\/p>\n<p><em>Cancer r\u00e9fractaire : cancer qui ne r\u00e9pond pas au traitement.<\/em><\/p>\n<p>Le fruquintinib (Fruzaqla) est une th\u00e9rapie cibl\u00e9e utilis\u00e9e dans le traitement des patients atteints d&rsquo;un cancer colorectal m\u00e9tastatique lourdement pr\u00e9trait\u00e9. Il s&rsquo;agit d&rsquo;un traitement utilis\u00e9 lorsque d&rsquo;autres traitements de r\u00e9f\u00e9rence tels que les normes de soins incluant les traitements chimioth\u00e9rapie \u00e0 base de fluoropyrimidine, d&rsquo;oxaliplatine et d&rsquo;irinot\u00e9can, les traitements anti-VEGF et les traitements anti-EGFR (le cas \u00e9ch\u00e9ant) n&rsquo;ont pas r\u00e9ussi \u00e0 contr\u00f4ler la maladie.<\/p>\n<p>Le fruquintinib a \u00e9t\u00e9 approuv\u00e9 aux \u00c9tats-Unis en novembre 2023 sur la base des r\u00e9sultats des essais cliniques internationaux FRESCO-2 et l&rsquo;essai clinique chinois FRESCO. Dans les deux essais, la survie globale moyenne des patients trait\u00e9s avec le fruquintinib a \u00e9t\u00e9 am\u00e9lior\u00e9e d&rsquo;environ 3 mois par rapport au groupe placebo qui a re\u00e7u les meilleurs soins de soutien.<\/p>\n<p>Actuellement, le fruquintinib n&rsquo;est pas disponible au Canada. Cancer colorectal Canada soumettra un recueille des observations et r\u00e9actions des patients qui ont re\u00e7u du fruquintinib pour le traitement du cancer colorectal m\u00e9tastatique r\u00e9fractaire, afin de promouvoir un meilleur acc\u00e8s \u00e0 ce traitement pour les patients canadiens. Nous croyons fermement que les patients devraient avoir acc\u00e8s \u00e0 une gamme d&rsquo;options th\u00e9rapeutiques efficaces, en particulier dans le cas du cancer m\u00e9tastatique.<\/p>\n<p>Source\u00a0: <a href=\"https:\/\/ascopost.com\/issues\/march-10-2024\/fruquintinib-in-refractory-metastatic-colorectal-cancer\/\" target=\"_blank\" rel=\"noopener\">https:\/\/ascopost.com\/issues\/march-10-2024\/fruquintinib-in-refractory-metastatic-colorectal-cancer\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Avril 2024 Cancer r\u00e9fractaire : cancer qui ne r\u00e9pond pas au traitement. Le fruquintinib (Fruzaqla) est une th\u00e9rapie cibl\u00e9e utilis\u00e9e dans le traitement des patients atteints d&rsquo;un cancer colorectal m\u00e9tastatique lourdement pr\u00e9trait\u00e9. Il s&rsquo;agit d&rsquo;un traitement utilis\u00e9 lorsque d&rsquo;autres traitements de r\u00e9f\u00e9rence tels que les normes de soins incluant les <a href=\"https:\/\/www.colorectalcancercanada.com\/fr\/blogue\/le-fruquintinib-dans-le-traitement-du-cancer-colorectal-metastatique-refractaire\/\">&#8230;<\/a><\/p>\n","protected":false},"author":5,"featured_media":12470,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_tribe_ticket_capacity":"0","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[98,42],"tags":[],"class_list":["post-12418","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research-updates-fr","category-blogue"],"_links":{"self":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts\/12418","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/comments?post=12418"}],"version-history":[{"count":0,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts\/12418\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/media\/12470"}],"wp:attachment":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/media?parent=12418"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/categories?post=12418"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/tags?post=12418"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}